Transcendental Meditation in Veterans and First Responders With PTSD
Trial Snapshot
- Phase
- Not Applicable
- Status
- Terminated
- Enrollment
- 55
- Locations
- 5
- Primary Endpoint
- Change in PTSD symptoms over time
Study Overview
Brief Summary
The present study is part of a Phase 3 multi-site clinical trial that will recruit veterans and first responders diagnosed with PTSD, where they will be randomized to receive either Transcendental Meditation (TM) or Present Centered Therapy (PCT). Five assessments will be conducted, at: 1) baseline, 2) midpoint, 3) posttreatment, 4) three months posttreatment and 5) six months posttreatment. All assessments will be completed using remote HIPAA-compliant videoconferencing. The study protocol at NYSPI/Columbia will also include Magnetic Resonance Imaging (MRI) before and after treatment to elucidate neural predictors and mechanisms of these two treatment approaches.
Enrollment will include veterans and first responders with PTSD. Both TM and PCT will be provided by trained staff receiving weekly supervision. This trial is funded by the David Lynch Foundation and will recruit approximately 360 veterans and first responders over a three-year period.
Detailed Description
PTSD is among the most common and disabling problems for veterans and first responders. Although PTSD from combat-related events is widely known, veterans and first-responders also face traumatic experiences from other events including sexual trauma, accidents, and injuries. Recent findings, for example, indicated that nearly a quarter of female Veterans experienced sexual assault when in the military.
At present, the non-medication therapies for PTSD with the strongest scientific support include Prolonged Exposure (PE), Cognitive Processing Therapy (CPT), and Eye Movement Desensitization and Reprocessing (EMDR). While many patients with PTSD benefit from these therapies, research indicates that these psychotherapies appear to be less effective for veterans than for civilians with PTSD, and many veterans may remained symptomatic in the long run. Based on this evidence, there is a clear need for new PTSD treatments that are effective for and amenable to the unique circumstances of veterans and first-responders.
Transcendental Meditation (TM) is a promising intervention. A phase 2 clinical trial, funded by the Department of Defense and conducted at the San Diego VA, showed that TM significantly reduces both PTSD symptom severity and depression in a veteran population, with post-hoc analysis indicating reduced suicidal ideation. Relative to conventional PTSD treatments that aim to improve symptoms through mechanisms such as habituation to anxiety-provoking stimuli and desensitization to trauma-related memories, TM improves symptoms by aiming to calm down the nervous system.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Double (Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •General Inclusion Criteria:
- •Prior or current military service OR prior or current work as a first responder (law enforcement, firefighters, and EMS)
- •Active and primary diagnosis of PTSD with symptom duration ≥ 3 months
- •CAPS-5 score ≥ 25 at intake assessment
- •Age 18 - 80
- •Able to give consent, English literate
Exclusion Criteria
- •Previous or current treatment with Transcendental Meditation, Present Centered Therapy, or any current psychotherapy.
- •Current severe alcohol/cannabis use disorder or any other current substance use disorder except nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are allowed)
- •History of or present psychiatric diagnosis of psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder
- •Current diagnosis of bipolar disorder
- •Active suicidal or homicidal ideation or suicide attempt within two years of study enrollment
- •Psychiatric hospitalization in the past six months
- •Intent to change or begin new psychotherapy or other meditation therapy during 3-month study treatment
- •Intent to enroll in another research study testing an experimental intervention during three-month period of study intervention
- •Recent psychotropic medication dosage change or initiation within the three months prior to study enrollment
- •Intent to change dosage of or initiate new psychotropic medication during the three-month period of study intervention
- •Medical illness that could interfere with assessment of diagnosis, such as organic brain impairment or unstable thyroid disease
- •Current unstable medical illness
- •MRI Inclusion Criteria:
- •Prior or current military service OR prior or current work as a first responder (law enforcement, firefighters, and/or EMS)
- •Active and primary diagnosis of PTSD with symptom duration ≥ 3 months
- •CAPS-5 score ≥ 25 at intake assessment
- •Age 18 - 80
- •Able to give consent, English literate
- •Right handed
- •MRI Exclusion Criteria:
- •Previous or current treatment with Transcendental Meditation, Present Centered Therapy, or any current psychotherapy.
- •Current severe alcohol/cannabis use disorder or any other current substance use disorder except nicotine (i.e., nicotine use disorder and mild-moderate alcohol/cannabis use disorder are allowed)
- •History of or current psychiatric diagnosis of psychotic episode, psychotic disorder, schizophrenia, schizoaffective disorder
- •Current diagnosis of bipolar disorder
- •Active suicidal or homicidal ideation or suicide attempt within two years of study enrollment
- •Psychiatric hospitalization in the past six months
- •Intent to change or begin new psychotherapy or other meditation therapy during 3-month study intervention
- •Intent to enroll in another research study testing an experimental intervention during three-month period of study intervention
- •Recent psychotropic medication dosage change or initiation within the three months prior to study enrollment
- •Intent to change dosage of or initiate new psychotropic medication during the three-month period of study intervention
- •Paramagnetic metallic implants or devices contraindicating magnetic resonance imaging or any other non-removable paramagnetic metal in the body.
- •Medical illness that could interfere with assessment of diagnosis, such as organic brain impairment or unstable thyroid disease
- •Current unstable medical illness
- •Any condition that would exclude clinical MRI exam (e.g. pacemaker, paramagnetic metallic prosthesis, surgical clips, shrapnel, necessity for constant medicinal patch, some tattoos)
- •Significant claustrophobia that would preclude ability to remain calm within the MRI scanner
- •Females who are pregnant or breastfeeding, or plan to become pregnant during the period of the study.
Arms & Interventions
Transcendental Meditation (TM):
TM treatment for PTSD is designed to reduce stress, facilitate deep rest, and increase well-being. It was originally conceptualized as an effortless technique to enable physical relaxation. The treatment will be delivered by experienced, certified TM instructors receiving weekly supervision.
Intervention: Transcendental Meditation (TM) (Behavioral)
Present Centered Therapy (PCT):
PCT is a focused time-limited treatment for PTSD that focuses on increasing adaptive responses to current life stressors and difficulties that are directly or indirectly related to trauma or PTSD symptoms. PCT was originally designed as a treatment comparator in trials evaluating the effectiveness of trauma-focused cognitive-behavioral therapies such as PE and CPT. Several clinical trials have indicated that PCT may be an effective treatment option for PTSD and that patients may drop out of PCT at lower rates relative to trauma focused forms of CBT.
Intervention: Present Centered Therapy (PCT) (Behavioral)
Outcomes
Primary Outcomes
Change in PTSD symptoms over time
Time Frame: Baseline, At 6 weeks, Post-treatment: approximately 3 months and 6 months from intake
Change in symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5: ranging from 0-80) from pre- to post-treatment. Lower scores indicate lower symptom levels of PTSD.
Secondary Outcomes
- Change in depressive symptoms over time(Baseline, At 6 weeks, Post-treatment: approximately 3 months and 6 months from intake)
Investigators
Yuval Y Neria
Professor of Medical Psychology
Research Foundation for Mental Hygiene, Inc.